The p53 paralog TPp73 gene gives rise to a variety of functionally distinct polypeptides involved in the control of growth arrest, apoptosis and differentiation. Multiple TA (transactivation competent, pro-apoptotic and anti-proliferative) p73 carboxy-terminal splicing isoforms (a, b, g, d, e, z, Z and Z 1 ) are expressed from the P1p73 promoter (reviewed by Giombini et al 1 and references therein). A second intragenic promoter, P2p73, controls the expression of dominantnegative (DN) variants that lack the amino-terminal transactivation domain and act as dominant-negative repressors of p53-and p73-dependent apoptosis (reviewed by Giombini et al 1 and references therein). Changes in TAp73 and DN-p73 expression rather than inactivating mutations within the TP73 gene, have been described in many human tumors. 2 Unlike acute lymphoid leukemias, which mainly display promoter CpG islands hypermethylation, acute myeloid leukemia is characterized by a relative enrichment of shorter TAp73 isoforms, and in the case of acute promyelocytic leukemia (APL), a peculiar lack of DN-p73 expression has been reported by our group. [3] [4] [5] In this study, we have investigated the molecular mechanisms underlying the transcriptional repression of the P2p73 promoter that leads to the severe reduction of DN-p73 expression in APL blasts. We identified the promyelocytic leukemia (PML)/RARa fusion protein as a direct regulator of the P2p73 transcriptional activity and showed that retinoic acid (RA) treatment relieves P2p73 repression in vitro and restores DN-p73 expression in APL patients in vivo. Notably, we found that DN-p73 expression acts as a pro-differentiation factor in APL cells.
Sequence analysis and binding-site scanning of the P2p73 promoter reveals, in addition to the well-characterized p53 and AP1 sites, the presence of five conserved putative RA-responsive element (RARE) sites (positions À5242 À5209; À4413 À4372; À3843 À3826; À3081 À3043; À2871 À2824) and several RARE half-sites (Figure 1a) . By generating deletion mutants of the P2p73 promoter, we found that deletion of a large genomic fragment containing either the putative RARE elements (P2-2500) or several RARE half sites (P2-1500) results in an increase of the basal transcriptional activity of the P2p73 promoter (Figure 1b , left panel). The transcriptional activity of the P2-55 promoter deletion mutant returns to levels comparable to those of the full-length P2-5800 promoter, thus suggesting the presence of positive regulatory elements between positions -5800 and -1500 (Figure 1b, left panel) . To analyze the transcriptional effects of the PML/RARa fusion protein on the P2p73 promoter, we performed transactivation assays using the deletion mutants described above (Figure 1a) . We found that exogenously expressed PML/RARa severely downregulates the P2-5800, P2-2500 and P2-1500 promoter constructs, whereas it has no effect on the P2-55 promoter mutant (Figure 1b , right panel). By using crosslinked chromatin derived either from PR9 cells, a U937-derived cell line in which exogenous PML/RARa expression is Zinc-inducible, or from NB4 promyelocytic leukemia cells, we found that PML/RARa is recruited in vivo onto multiple sites in the P2p73 promoter ( Figure 1a , right panel; Figure 1c ). Altogether, these findings indicate that PML/RARa fusion protein binds to and inhibits the transcriptional activity of the P2p73 promoter.
Several in vitro and in vivo studies have shown that RA treatment blocks PML/RARa activity either by inducing changes in the composition of chromatin-bound PML/RARa complexes or by directing PML/RARa to degradation, thus relieving its repressive effects on RA target genes transcription. 6 Indeed, we found that RA treatment of PR9 cells determined a significant reduction of the PML/RARa fusion protein bound to the P2p73 promoter ( Figure 1c , upper panel; Supplementary Figure 1) . A similar pattern of PML in vivo binding to the DN-p73 promoter was also found in NB4 cells (Figure 1c , lower panel). It has been shown previously that the binding of PML/RARa to the promoter of its transcriptional target gene RARb2 is not affected upon RA treatment. 7 The switch from repression to transcriptional activation has been related to the substitution of HDAC1-containing complexes with transcriptionally active PML/RARa-p300 protein complexes. 7 Although we cannot exclude that the small amount of PML/RARa still bound to P2p73 promoter ( Figure 1c ) may be engaged in transcriptionally active complexes, our results strongly suggest that the actual amount of PML/RARa recruited in vivo is critical for the transcriptional repression of the P2p73 promoter. Our findings could also be explained by the existence of different subsets of PML/RARa target genes whose transcriptional control is exerted through distinct molecular mechanisms. Furthermore, transactivation assays confirmed that the inhibitory effect of PML/RARa on the P2p73 promoter is reversed in the presence of RA (Figure 1d 
Figure 1
Letters to the Editor Finally, to further evaluate whether RA-mediated release of DN-p73 expression from PML/RARa transcriptional repression is recapitulated in APL patients, we analyzed DN-p73 mRNA expression in blasts from 22 APL patients before and after conventional RA treatment. In agreement with our previous observation, 4 we found that DN-p73 expression is Putative RA-responsive elements, the E-box-like sites, the AP1-binding site, the p53-responsive elements (RE) and the TATA box position are indicated. R1, R2, R3 and R4 identify the P2p73 promoter regions containing the five conserved RAREs. The P2-p73-RARE-luc (-5800) reporter construct was obtained by cloning into the luciferase reporter plasmid pGL3-basic (Promega Inc), a 5.8-kb PCR fragment of the genomic region located upstream the putative transcription initiation site of DN-p73 mRNA. Deletion mutants were obtained using standard cloning techniques. Sequence analysis confirmed the identity with the sequence present in Genebank. Right panel: location of the RARE sites in the P2p73 promoter sequence. Canonical RARE half sites are indicated by boxes. The arrows show the promoter regions amplified by specific primer pairs. (b) Left panel: basal activity of the P2p73 promoter and its deletion mutants. H1299 cells were transiently co-transfected, using the calcium phosphate method, with the indicated luciferase reporter plasmids and with the Renilla-encoding pRL-null plasmid. At 24 h after transfection, cells were lysed and luciferase activity quantified using the Dual Luciferase Reporter kit (Promega Inc.). Renilla activity was used to normalize the transfection efficiency. Results are expressed as fold activation relative to the basal activity of P2p73-RARE-luc-5800. Error bars represent two standard deviations calculated on two independent experiments. Right panel: dose-dependent repression on the full-length P2p73 promoter by PML/RARa and its effects on the different promoter deletion mutants. H1299 cells were co-transfected with 0.5-1 mg of the pSG5-PML/RARa expression vector together with the indicated P2p73 promoter constructs. Results are expressed, after normalization to the renilla luciferase activity, as fold activation relative to the basal activity of each P2p73 deletion mutant. Results are expressed as fold activation relative to the basal activity of P2-p73-RARE-luc-5800 promoter. (e) PML/RARa (left panel) and DN-p73 (right panel) mRNA levels in non-induced and Zn þ -induced (100 mM) PR9 cells either untreated or treated with RA (2 mM). cDNAs were amplified by qRT-PCR using primer pairs and TaqMan probe sets specific for PML/RARa or DN-p73. ABL mRNA transcript was used as control to correct for RNA quality differences. The sequence of primer pairs and probe sets are available upon request. Upper boxes in (e): immunoblotting analysis of PML/RARa induction by Zn þ in PR9 cells. (f) Effect of DN-p73 expression on APL cell line NB4 differentiation. NB4 cells were electroporated either with an empty vector (pDsRed1, Clontech) or with the corresponding DN-p73 expression vector (pDsRed1-DN-p73) and analyzed for cell morphology (left panel) and membrane phenotype (right panel). Using a single-pulse protocol (voltage 260 V and capacitance 1050 F) and the Gene Pulser electroporation apparatus (Bio-Rad Laboratories, Hercules, CA, USA), we consistently reached a transfection efficiency of 80% or more without significant reduction of cell viability (data not shown). At 24 h after transfection, cells were treated with RA for 1 or 2 days. In left panel, the morphological analysis of MGG-stained cytospin preparations of NB4-pDsRed1 and NB4-pDsRed1-DN-p73 cells either untreated (NT) or exposed for 24 hours to 2 mM RA ( þ RA, 24 h). Original magnification Â 400. Table (right Figure 3) .
Altogether, our findings show that DN-p73 is a transcriptional target of the PML/RARa oncogene. This results in the transcriptional repression of DN-p73 providing one potential molecular basis underlying the lack of DN-p73 expression in a large subset of APL leukemias. The role of PML/RARa in DN-p73 repression is confirmed by the ability of RA to restore its expression both in vitro and in vivo. The observation that DN-p73 expression induces a number of differentiation markers in APL cells and cooperates with RA-induced differentiation in vitro suggests that DN-p73 might be necessary for proper myeloid differentiation. Indeed, DN-p73 expression is modulated during muscle and kidney differentiation. 8, 9 Although DN-p73 has been mainly involved in the inhibition of p53-, TAp63-and TAp73-dependent transcription of target gene promoters containing p53REs, a series of recent evidences indicates that DN-p73 may directly and indirectly activate transcription from a number of target genes. 10 Thus, the ability of RA to remove the differentiation block of APL leukemias and to restore DN-p73 expression might result in the activation of a specific subset of yet unidentified genes involved in myeloid differentiation.
